Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure.
Nine patients with postoperative liver failure were treated with plasma exchange (PE) or PE and continuous hemodiafiltration (CHDF), and various biochemical parameters were determined before and after treatment. Although citrate levels increased significantly after treatment compared with pretreatment levels in both the PE group and the PE + CHDF group (P < 0.0001 and P < 0.0001, respectively), the percentage of the increase in citrate levels was significantly higher in the PE group than in the PE + CHDF group (P = 0.0051). Total bilirubin (T-Bil) levels were significantly lower after treatment in both the PE and PE + CHDF groups (P < 0.0001 and P = 0.0001, respectively). There were no significant differences in T-Bil levels between the two groups (P = 0.5181). There were no significant differences in interleukin (IL)-6 levels before and after treatment in both the PE and PE + CHDF groups (P = 0.1281 and P = 0.2273, respectively). IL-18 levels were significantly lower after treatment in both the PE and PE + CHDF groups (P < 0.0001 and P = 0.0002, respectively), but there were no significant differences in the removal rate of IL-18 in both the PE and PE + CHDF groups (P = 0.8749). These results indicate that combining PE and CHDF in a series-parallel circuit is an effective modality for suppressing the elevation of blood citrate levels. This finding may have important implications for the development of an effective treatment for patients with postoperative liver failure.
Yonekawa
Chikara
C
Department of Integrated Medicine, Division of Emergency and Critical Care Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. yone-c@sc4.so-net.ne.jp
Nakae
Hajime
H
Tajimi
Kimitaka
K
Asanuma
Yoshihiro
Y
D000368:Aged; D001663:Bilirubin / Q000097:blood; D019343:Citric Acid / Q000097:blood; D003131:Combined Modality Therapy; D005260:Female; D017583:Hemodiafiltration; D006498:Hepatectomy / Q000009:adverse effects*; D006801:Humans; D020382:Interleukin-18 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D017114:Liver Failure, Acute / Q000097:blood / Q000209:etiology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D016896:Treatment Outcome
D020382:Interleukin-18; D015850:Interleukin-6; D019343:Citric Acid; D001663:Bilirubin